Boadle D J, Tattersall M H
St Vincent's Hospital, Darlinghurst.
Aust N Z J Obstet Gynaecol. 1987 Nov;27(4):341-2. doi: 10.1111/j.1479-828x.1987.tb01023.x.
Mitoxantrone was administered to 12 patients with advanced or recurrent endometrial carcinoma of whom only 1 had received prior chemotherapy (chlorambucil). The drug was given every 21 days, the initial dose of either 12 mg/m1 or 14 mg/m1 being decided by the patient's age, timing of prior radiotherapy, tolerance of prior chemotherapy and baseline haematological parameters. One partial response was observed in the 11 patients evaluable for assessment of response. Mitoxantrone was well tolerated with the major toxicity being myelosuppression, particularly granulocytopenia. With the observed response rate of 9%, we conclude that mitoxantrone does not have significant activity in endometrial carcinoma.
米托蒽醌被用于治疗12例晚期或复发性子宫内膜癌患者，其中只有1例之前接受过化疗（苯丁酸氮芥）。药物每21天给药一次，初始剂量为12mg/m²或14mg/m²，根据患者年龄、之前放疗时间、对先前化疗的耐受性以及基线血液学参数来决定。在可评估疗效的11例患者中观察到1例部分缓解。米托蒽醌耐受性良好，主要毒性为骨髓抑制，尤其是粒细胞减少。鉴于观察到的缓解率为9%，我们得出结论，米托蒽醌在子宫内膜癌中没有显著活性。
